Nevro Corp. (NYSE:NVRO) Shares Bought by ArrowMark Colorado Holdings LLC

ArrowMark Colorado Holdings LLC raised its stake in shares of Nevro Corp. (NYSE:NVRO) by 2.4% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 4,391,258 shares of the medical equipment provider’s stock after buying an additional 102,150 shares during the period. ArrowMark Colorado Holdings LLC owned about 0.12% of Nevro worth $24,547,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its stake in shares of Nevro by 490.7% in the 2nd quarter. Assenagon Asset Management S.A. now owns 728,463 shares of the medical equipment provider’s stock valued at $6,134,000 after purchasing an additional 605,134 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of Nevro by 3,446.5% in the second quarter. Point72 Asset Management L.P. now owns 152,500 shares of the medical equipment provider’s stock valued at $1,284,000 after buying an additional 148,200 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Nevro by 154.1% during the 2nd quarter. Acadian Asset Management LLC now owns 241,186 shares of the medical equipment provider’s stock worth $2,029,000 after buying an additional 146,276 shares during the period. Millennium Management LLC lifted its position in shares of Nevro by 21.4% during the 2nd quarter. Millennium Management LLC now owns 956,542 shares of the medical equipment provider’s stock valued at $8,054,000 after buying an additional 168,573 shares in the last quarter. Finally, Engaged Capital LLC grew its stake in Nevro by 29.5% in the 3rd quarter. Engaged Capital LLC now owns 2,442,956 shares of the medical equipment provider’s stock valued at $13,656,000 after acquiring an additional 557,000 shares during the period. Hedge funds and other institutional investors own 95.52% of the company’s stock.

Nevro Trading Up 0.4 %

NVRO opened at $4.60 on Monday. Nevro Corp. has a one year low of $3.95 and a one year high of $22.64. The company has a debt-to-equity ratio of 0.67, a quick ratio of 3.76 and a current ratio of 5.02. The stock has a market capitalization of $172.36 million, a PE ratio of -2.43 and a beta of 0.93. The business’s 50 day moving average price is $4.97 and its 200 day moving average price is $6.86.

Nevro (NYSE:NVRO) last issued its quarterly earnings data on Monday, November 11th. The medical equipment provider reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.40. The firm had revenue of $96.60 million during the quarter, compared to the consensus estimate of $93.09 million. Nevro had a negative return on equity of 23.52% and a negative net margin of 16.54%. The company’s quarterly revenue was down 7.0% on a year-over-year basis. During the same period last year, the company earned ($0.65) EPS. As a group, equities research analysts expect that Nevro Corp. will post -2.43 EPS for the current year.

Analyst Ratings Changes

NVRO has been the subject of a number of research analyst reports. Royal Bank of Canada restated a “sector perform” rating and set a $7.00 price objective on shares of Nevro in a research report on Tuesday, November 12th. Citigroup cut their price objective on Nevro from $6.89 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, October 1st. StockNews.com raised Nevro from a “sell” rating to a “hold” rating in a report on Tuesday, November 19th. JMP Securities reiterated a “market perform” rating on shares of Nevro in a research report on Tuesday, November 12th. Finally, Truist Financial decreased their price objective on Nevro from $10.00 to $5.50 and set a “hold” rating on the stock in a report on Thursday, August 8th. Four analysts have rated the stock with a sell rating and eleven have given a hold rating to the company. According to data from MarketBeat, Nevro has a consensus rating of “Hold” and a consensus price target of $8.60.

Nevro Company Profile

Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems.